Case 1: Ponatinib In Chronic-Phase Cml

Case 1: Ponatinib in Chronic-Phase CML

Targeted Oncology

Ponatinib in chronic-phase CML patients with prior second generation TKI exposure

VJHemOnc – Video Journal of Hematology & HemOnc

OPTIC: Ponatinib in chronic-phase CML

VJHemOnc – Video Journal of Hematology & HemOnc

Safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients

VJHemOnc – Video Journal of Hematology & HemOnc

OPTIC: ponatinib in resistant chronic-phase CML

VJHemOnc – Video Journal of Hematology & HemOnc

Case 1: Molecular Testing & Treatment in CP-CML

Targeted Oncology

ASH 2021: New OPTIC Trial Analysis Shows Ponatinib is Effective in Chronic Myeloid Leukemia Patients

Five-year follow-up of OPTIC: ponatinib in CP-CML and its impact on mutational status

VJHemOnc – Video Journal of Hematology & HemOnc

Case 1: TKI Therapy in CP-CML

Targeted Oncology

Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial

VJHemOnc – Video Journal of Hematology & HemOnc

Is Ponatinib Safe for Treating CML?

Ponatinib (ICLUSIG) Mechanism of Action in Chronic Myeloid Leukaemia

Dr. Cortes Discusses Approval of Ponatinib for Adults with Chronic-phase CML

Interim Data Analysis Suggests Ponatinib to be Favorable TKI Treatment Among CML Patients

Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial

VJHemOnc – Video Journal of Hematology & HemOnc

Management of Thrombosis Risk with Ponatinib and other TKIs for CML?

Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting

VJHemOnc – Video Journal of Hematology & HemOnc

Multidisciplinary management of chronic myeloid leukaemia in the later-line setting

Touch Medical Media

Challenges in Management of Chronic Phase CML

Targeted Oncology

Phase I study of asciminib in patients with CP-CML carrying the T315I mutation

VJHemOnc – Video Journal of Hematology & HemOnc